Search

Your search keyword '"Abrescia N"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Abrescia N" Remove constraint Author: "Abrescia N"
219 results on '"Abrescia N"'

Search Results

51. Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice

52. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

53. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort

54. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

55. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008

56. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

57. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

58. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

59. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals

60. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort

61. Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy

62. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

63. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study

64. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy

65. TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

66. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy

67. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts

68. Insulin-Degrading Activity in Experimental Liver Cirrhosis of the Rat

69. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

70. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

71. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count

72. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

73. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

74. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study

75. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

76. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

77. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures

78. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

79. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

80. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort

81. Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects

82. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients

83. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

84. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

85. Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy

86. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

87. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

88. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

89. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

90. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

91. alphaVbeta6 is a novel receptor for human fibrillin-1. Comparative studies of molecular determinants underlying integrin-rgd affinity and specificity

92. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study

93. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

94. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

95. Economic evaluation of HIV treatments: The I.CO.N.A. cohort study

97. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

98. Lo studio di coorte I.CO.N.A. (Italian CohOrt Naive Antiretrovirals): caratteristiche all’arruolamento dei primi 1676 soggetti

99. Durability of FTC/TDF-containing cART regimens in a large cohort of HIV-infected patients seen for care in Italy

Catalog

Books, media, physical & digital resources